title: Analysis of the risk factors for febrile neutropenia in patients with bone and soft tissue sarcoma.
abstract: BACKGROUND
  Although systemic chemotherapy is inevitably selected as the modality of treatment for high-grade bone and soft tissue sarcoma (BSTS), limited information is available regarding febrile neutropenia (FN).
  
  
  METHODS
  FN incidence, blood culture results and risk factors were analyzed in 35 patients with high-grade BSTS.
  
  
  RESULTS
  FN occurred in 51% of the patients and 24% of the courses of systemic chemotherapy. Culture results indicated pathogen in only 33.3% of patients who had FN. Methicillin-resistant Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus were frequently observed. Body weight of less than 61.0 kg and a tumor originating from the bone in a patient-based analysis, and serum albumin <4.2 g/dl and having a source of infection in a course-based analysis were independent risk factors for FN.
  
  
  CONCLUSIONS
  Considerably high risks for FN during chemotherapy for BSTS were confirmed. The risk factors presented here appeared to differ from those in previously reported guidelines.
authors: Department of Orthopedic Surgery, Faculty of Medicine, Kyorin University, Mitaka, Tokyo Japan.
authors: Takayuki
authors: T
authors: Aoyagi
authors: Department of Orthopedic Surgery, Faculty of Medicine, Kyorin University, Mitaka, Tokyo Japan t-morii@gb3.so-net.ne.jp.
authors: Takeshi
authors: T
authors: Morii
authors: Department of Orthopedic Surgery, Faculty of Medicine, Kyorin University, Mitaka, Tokyo Japan.
authors: Takashi
authors: T
authors: Tajima
authors: Department of Orthopedic Surgery, Faculty of Medicine, Kyorin University, Mitaka, Tokyo Japan.
authors: Akira
authors: A
authors: Yoshiyama
authors: Department of Orthopedic Surgery, Faculty of Medicine, Kyorin University, Mitaka, Tokyo Japan.
authors: Shoichi
authors: S
authors: Ichimura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000473:pathology* / Q000628:therapy; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012509:Sarcoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
keywords: Febrile neutropenia; bone and soft tissue sarcoma; chemotherapy